Dear Editor, {#Sec1}
============

During the last epidemic season of bronchiolitis, we performed a single center, retrospective analysis in our infant with GA between 30^+ 0^ and 32^+ 6^ weeks and age \< 12 months to compare frequency and characteristics of bronchiolitis and bronchiolitis-related hospitalization, in two consecutive epidemic seasons (S1 vs S2). In S1 (May 1st 2015 to March 31st 2016) 35 newborns had received prophylaxis with PLV (according to 2015 AIFA guidelines allowing prophylaxis to all newborn with a \< 35 week of gestational age and with less of 6 months at the start of epidemic season, identified in in Italy from October to April); in S2 (May 1st, 2016 to March 31st, 2017) 47 newborns of the same gestational age did not receive prophylaxis due to a modification of AIFA indications for prophylaxis limiting it only to newborns \< 30 weeks of gestational age (October 2016) \[[@CR1]\]. In S2 vs. S1, we observed a rising trend in rates of bronchiolitis and bronchiolitis-related hospitalization and of morbidity with an increase in the rate of mechanical ventilation and a reduction in the age of hospitalization for bronchiolitis in S2 \[[@CR2]\].

In November 2017, AIFA indications authorized again prophylaxis for preterm ≤35 weeks of GE and with less of 6 months at the start of epidemic season \[[@CR3]\]. Therefore, infants with GE 30^+ 0^ to 32^+ 6^ regularly received PLV in the S3 epidemic season (S3, years 2017--2018 from May 1st, 2017 to May 31st, 2018).

In order to assess, any potential clinical impact of the different path of prophylaxis, we then compared the incidence of bronchiolitis and the characteristics of the bronchiolitis-related hospitalization between S1, S2 and S3 in inborn infants of 30^+ 0^--32^+ 6^ weeks gestational age. Our data were reported in Table [1](#Tab1){ref-type="table"}.Table 1Clinical characteristic of three groups (WGE = week of gestational age)S1 (2015--2016)S2 (2016--2017)S3 (2017--2018)*P* value^\*^Newborn with WGE 30^+ 0^--32^+ 6^354756Mean gestational age30,93131,5Newborn with WGE \< 31 sett (30^+ 0^--30^+ 6^)16/35 (45,7%)18/47 (38,3%)16/56 (28,57%)*P* = 0.29Newborn treated with PLV27256*P* \< 0,00001Number of bronchiolitis6/35 (17%)12/47 (26%)6/56 (10,7%)*P* =0.048Hospitalized for bronchiolitis3/6 (50%)6/12 (50%)3^a^/6 (50%)*P* = 1Absolute percentage of admissions3/35 (8,6%)6/47 (12,8%)3/56 (5,3%)*P* =0.184Intubation at birth3/3 (100%)4/6 (66,7%)0/3 (0%)*P* = 0,16Age at the admission (Months)74.33^b^Intubation at admission1/3 (33,3%)2/6 (33,3%)1^c^/3 (33,3%)*P* = 1^**\***^all statistical analysis was performed comparing S2 with S3^a^All 3 preterm had received only one dose of palivizumab before having bronchiolitis^b^All 3 preterm had received only one dose of palivizumab before having bronchiolitis and were born in full epidemic season^c^newborn who had received only one dose of palivizumab

During the 2017--2018 epidemic season, according to the new AIFA recommendations for 2017, all 56 infants of 30^+ 0^--32^+ 6^ GE underwent PLV prophylaxis. The percentage of bronchiolitis declined from 26% (12/47) in S2 to 10,7% in S3 (6/56). Hospital admissions for bronchiolitis were 3/6 (50%), like the previous season, but all the three admissions with one treated at home had received only one dose of PLV before contracting bronchiolitis, hence without a full course of adequate prophylaxis; additional 2 children developed a mild form and were treated at home. Although there is a slight difference in the average gestational age of newborns between S2 and S3 (with a higher GE in S3) we believe that this difference does not affect the results of the study, particularly the major EG of S3 is not the factor determining the lower incidence of bronchiolitis. In fact, in S2, 10 of 12 infants with bronchiolitis had a lower EG (30--30^+ 6^), while in S3 of 6 infants with bronchiolitis only 1 had the lowest EG (30--30^+ 6^): this shows that in the epidemic season without prophylaxis (S2) as expected, the most premature infants are affected, while in the epidemic season in which prophylaxis is carried out (S3) the youngest are protected in almost all cases and those affected by bronchiolitis are those with high gestational age.

The mean chronological age at hospitalization for bronchiolitis was 3 months, but they were all newborns (4) who had received only one dose of PLV and three of them were born in full epidemic season. In S3 only one newborn needed intubation during the hospitalization for bronchiolitis and he had received only one dose of PLV.

Overall, our observations confirm the efficacy of prophylaxis with PLV in infants 30--32 weeks GE, which in S3 were protected by bronchiolitis in almost all cases and indicating that the most severe forms requiring hospitalization and intubation would have potentially been equal to zero if the only hospitalized and intubated infant had time to complete the PLV treatment cycle.

Although such data cannot be generalized, our personal experience suggests that prophylaxis with PLV in preterm of this gestational age is a good medical practice and should not be further modified.
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